Abstract
Objectives Production of anti-citrullinated peptide/protein antibodies (ACPA) is characteristic for rheumatoid arthritis (RA) and may inform about biological pathways involved in disease development in specific subgroups. Since multiple loci in genome wide association screens have been implicated in RA risk, we investigated the association between genetic variations and the development of multiple types of ACPA in three big cohorts of RA patients from Sweden, USA and UK (EIRA, NARAC and WTCCC) with overall 6,127 individuals with RA.
Methods We combined genotyping data from Illumina Immunochip with serological data for 16 ACPA specificities from a custom-made multiplex microarray (Thermo Fisher Scientific, ImmunoDiagnostic division). A logistic regression-based association test in each cohort was followed by meta-analysis.
Results We report several loci, harbouring three or more variants associated with ACPA, reaching study-wide significance (FDR<0.1) – PTPN22, LINC02341_TNFSF11, THADA and TMEM174. Most of these loci are not known to be associated with RA. Stratification by “shared epitope” (SE) alleles indicated an association between the PTPN22 locus and levels of antibodies binding to the vimentin peptide, Cit-Vim60-75, in SE positive cases, but not in SE negative cases.
Conclusion Our data identifies several new loci which associate with subsets of RA characterized by presence of specific ACPA and indicate unknown disease heterogeneity.
What is already known about this subject?
ACPA define two subgroups within RA, and has been an important biomarker included in diagnostic criteria
Commonly used ACPA test, anti-CCP, accumulate signals from autoantibodies to several peptides and does not discriminate between multiple autoantibody specificities.
What does this study add?
Our study demonstrates that different sets of ACPAs in RA have distinct genetic associations. Associated variants from our study localize in known regulatory regions and have transcriptomic effects beyond the associated locus
We find that PTPN22 locus can drive positivity for multiple APCAs, while other found loci associate with specific autoantibody positivities
How might this impact on clinical practice?
Our study will extend personalized approach in handling of rheumatoid arthritis with focus on serologically defined subgroups of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been made possible by research grants and fellowships from Swedish grant agencies Reumatikerförbundet, Stiftelsen Börje Dahlins Fond, Stiftelsen Jubileumsklinikens Forskningsfond, and Vetenskapsrådet
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval information: Stockholm Regional Ethics Committee: Dnr 96-174, 02-288, 210/935-31/1, 2021-00125.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request
